CSIMarket
 
Geovax Labs Inc   (GOVX)
Other Ticker:  
 
 
Price: $2.3500 $-0.19 -7.480%
Day's High: $2.52 Week Perf: -13.28 %
Day's Low: $ 2.34 30 Day Perf: -29.29 %
Volume (M): 18 52 Wk High: $ 3.76
Volume (M$): $ 43 52 Wk Avg: $0.72
Open: $2.50 52 Wk Low: $0.25



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Geovax Labs Inc
GeoVax Labs Inc. is a biotechnology company that focuses on developing innovative vaccines to prevent and treat infectious diseases, including HIV/AIDS. The company utilizes a unique vaccine platform called Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) to design and develop its vaccines. This platform allows for the production of non-infectious virus-like particles that mimic the target virus, triggering an immune response to provide protection against the actual virus.

GeoVax Labs' vaccines are designed to be safe, effective, and easy to produce, making them suitable for large-scale distribution. The company has dedicated significant efforts into developing an effective HIV/AIDS vaccine that can provide a durable and long-lasting immune response. Additionally, GeoVax Labs is exploring opportunities to apply its MVA-VLP platform for the development of vaccines against other infectious diseases, such as Zika, Ebola, and Lassa fever.

With a team of experienced scientists and researchers, GeoVax Labs is committed to advancing the field of vaccine development and public health. The company collaborates with various research institutions, government agencies, and pharmaceutical companies to accelerate the progress of its vaccine programs. By addressing global health challenges, GeoVax Labs strives to make a positive impact on the lives of millions of individuals worldwide.


   Company Address: 1900 Lake Park Drive, Suite 380 Smyrna 30080 GA
   Company Phone Number: 384-7220   Stock Exchange / Ticker: NASDAQ GOVX
   GOVX is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

GeoVax Labs Implements Reverse Stock Split to Strengthen Market Position and Comply with Nasdaq Standards

Published Mon, Jan 29 2024 2:00 PM UTC

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Atlanta, GA - January 29, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a leading biotechnology company specializing in immunotherapies and vaccines against cancers and infectious diseases, recently announced its approval for a reverse stock split at a ratio of 1-for-15. The...

Geovax Labs Inc

Geovax Labs Inc Witnesses Alarming Decline in Corporate Conduct during Third Quarter of 2023

The Major Pharmaceutical Preparations sector analysts have recently shifted their focus to analyzing the third quarter results of 2023. A notable observation among these analysts is the operating deficit of $-8.599754 million from GeoVax Labs Inc (GOVX), a biotechnology company specializing in the development of immunotherapies and vaccines for cancers and infectious diseases. While the company has not disclosed any information regarding its top-line yet, there is significant interest in their upcoming July to September 30, 2023 reporting season.
To better contextualize this performance, it is essential to refer back to the third quarter of 2022. During that period, GOVX reported an operating deficit of $-3.970533 million. Although the present top-line figures remain undisclosed, assessing the company's previous performance offers some reference points. Unfortunately, the most crucial finding from the third quarter of 2023 earnings season, apart from the absence of top-line information, is the considerable increase in the net deficit. This deficit now stands at $-8.409 million, growing substantially from $-3.968 million in the third quarter of 2022.

Geovax Labs Inc

Geovax Labs Inc Faces Scrutiny: Q2 Operating Shortfall Triples to $-6.1 Million

Geovax Labs Inc, a major player in the Pharmaceutical Preparations sector, has recently come under scrutiny as experts analyze its second-quarter performance for 2023. The company has reported an operating shortfall of $-6.178821 million for the period of April to June 30, 2023. As of now, Geovax Labs Inc has not provided any top-line figures for this reporting period.
To gain perspective on the company's recent results, it is essential to compare them with its performance in the second quarter of 2022. During that period, Geovax Labs Inc reported an operating shortfall of $-2.242488 million. This indicates that the deficit has significantly increased in the fiscal second quarter of 2023, reaching $-5.928 million.

Geovax Labs Inc

Major Pharmaceutical Preparations Company Faces Lackluster Revenue throughout Latest Fiscal Period

Geovax Labs Inc is a biotechnology company that focuses on developing innovative vaccines for various infectious diseases. The company's primary goal is to formulate effective vaccines for the prevention and treatment of HIV/AIDS.
The company's recent financial results for the fiscal period showed a mixed bag of results. Geovax Labs Inc experienced a reduction in the net loss per share, which decreased from $0.34 to $0.15 compared to the previous year. However, the company's deficit grew from $0.13 per share from the previous financial reporting period. Furthermore, the company reported a loss of $4.038 million, up from $2.428 million the previous year.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com